Table of Content

1 Market Guides
1.1 Liquid Biopsy Market - Strategic Situation Analysis & Impact of COVID-19
1.2 Guide for Executives, Marketing, Sales and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors


2  Introduction and Market Definition
2.1 What is Liquid Biopsy?
2.2 The Sequencing Revolution
2.3 Market Definition
2.3.1 Revenue Market Size
2.4 Methodology
2.4.1 Authors
2.4.2 Sources
2.5 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic
2.5.1 Global Healthcare Spending
2.5.2 Spending on Diagnostics
2.5.3 Important Role of Insurance for Diagnostics


3 Market Overview
3.1 Players in a Dynamic Market
3.1.1 Academic Research Lab
3.1.2 Diagnostic Test Developer
3.1.3 Genomic Instrumentation Supplier
3.1.3.1 Cell Separation and Viewing Instrumentation Supplier
3.1.4 Pharmaceutical/Reagent Supplier
3.1.5 Independent Testing Lab
3.1.6 Public National/regional lab
3.1.7 Hospital lab
3.1.8 Physician Lab
3.1.9 Audit Body
3.1.10 Certification Body.
3.2 Using Biopsies
3.2.1 Cancer
3.2.2 Precancerous conditions
3.2.3 Inflammatory conditions
3.3 Biopsy Sites
3.4 The Situation Today - Biopsy Analysis
3.5 Evidence of Cancer - Liquid Biopsy Technology
3.5.1 The Big Picture on Liquid Biopsy Technology
3.5.2 The Role of CTCs
3.5.2.1 Types of CTCs
3.5.2.2 CellSearch Detection - Ultimate Sensitivity
3.5.2.3 Epic Sciences Detection - Imaging Takes the Lead
3.5.2.4 Maintrac Detection - The Microscope
3.5.2.5 Other Methods
3.5.3 ctDNA - Going Mainstream?
3.5.4 Exosomes and Micro Vesicles - New Kid on the Block
3.5.5 The Multiple Play
3.6 Cancer Treatment Protocol Under Siege
3.6.1 Issues to Liquid Biopsy Adoption - Double Diagnostics
3.6.2 The Cancer Screening Market Opportunity
3.6.2.1 GRAIL - What Is It?
3.6.3 Cancer Management vs. Diagnosis
3.6.3.1 The Role of Risk Assessment
3.6.3.2 Managing Therapy
3.6.3.3 Monitoring Disease - What Is It?
3.6.4 Phases of Adoption - Looking into The Future
3.6.5 The Promise of Liquid Biopsy
3.7 Structure of Industry Plays a Part
3.7.1 Hospital Testing Share
3.7.2 Economies of Scale
3.7.2.1 Hospital vs. Central Lab
3.7.3 Physician Office Lab’s
3.7.4 Physician’s and POCT


4 Market Trends
4.1 Factors Driving Growth
4.1.1 Non Invasive Game Changer
4.1.2 Lower Cost
4.1.3 Greater Accuracy
4.1.4 Wide Range of Potential Uses
4.1.5 Aging Population
4.2 Factors Limiting Growth
4.2.1 Lower prices
4.2.2 Lack of Standards
4.2.3 Protocol Resistance
4.2.4 Initial Adoption Cost
4.2.5 COVID-19
4.3 Instrumentation and Automation
4.3.1 Instruments Key to Market Share
4.3.2 Bioinformatics Plays a Role
4.4 Diagnostic Technology Development
4.4.1 Next Generation Sequencing Fuels a Revolution
4.4.2 Impact of NGS on pricing
4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
4.4.4 CGES Testing, A Brave New World
4.4.5 Biochips/Giant magneto resistance based assay


5 Liquid Biopsy Recent Developments
5.1 Recent Developments - Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
5.2 Invitae to Expand Cancer Testing Portfolio
5.3 Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies
5.4 IVBH Bio Takes Aim at With Liquid Biopsy Incubator
5.5 Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership
5.6 Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech
5.7 BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy
5.8 EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform
5.9 Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding
5.10 Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition
5.11 Bio-Techne to Acquire Asuragen for up to $320M
5.12 Personalis Broadens Liquid Biopsy Offering
5.13 Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition
5.14 Delfi Diagnostics Plans Multi-Cancer Screening Test
5.15 Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response
5.16 Liquid Biopsy NGS Panels - Diverse Test Claims
5.17 CMS Colon Cancer Screening Memo Bodes Well for Assays
5.18 Natera Liquid Biopsy Test Coverage to Expand
5.19 Freenome Closes Financing to Support Early Cancer Detection Trial
5.20 C$2.6M Liquid Biopsy Initiative
5.21 NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy
5.22 Liquid Biopsy Shows Promise as Screen for Cancers
5.23 Inivata launches RaDaR™ for the detection of residual disease and recurrence
5.24 Liquid Biopsy Assay Detects 50+ Types of Cancer
5.25 Liquid Biopsy Study Confirms Concordance with Tissue Biopsy
5.26 Guardant Health Liquid Biopsy Expands Medicare Coverage
5.27 Aethlon Medical Lands Grant for Exosome Isolation Device
5.28 Biolidics to Develop Liquid Biopsy Breast Cancer Test
5.29 Liquid Biopsy Equal to Tissue to Indicate Immunotherapy Response
5.30 Exact Sciences buys Genomic Health
5.31 Multi-Gene Liquid Biopsy Breast Cancer Panel
5.32 Bio-Techne receives FDA breakthrough device for prostate cancer liquid biopsy
5.33 Thrive to Develop Earlier Detection of Multiple Cancer Types
5.34 Guardant Health Liquid Biopsy Test to be Covered by EviCore
5.35 Liquid biopsy combines Illumina’s ‘ultradeep’ sequencing with Grail’s machine learning
5.36 Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services
5.37 Natera Commercializes Tumor Whole Exome Sequencing from Plasma
5.38 Sienna Buys Liquid Biopsy & Exosome Isolation Technology


6 Profiles of Key Players
6.1 Abbott Diagnostics
6.2 AccuraGen Inc.
6.3 Acuamark Diagnostics
6.4 Admera Health, LLC
6.5 Agena Bioscience, Inc.
6.6 Agilent
6.7 Amoy Diagnostics Co., Ltd.
6.8 Anchor Dx
6.9 ANGLE plc
6.10 ApoCell, Inc.
6.11 ArcherDx, Inc.
6.12 Asuragen
6.13 AVIVA Biosciences
6.14 Baylor Miraca Genetics Laboratories
6.15 Beckman Coulter, Inc.
6.16 Becton, Dickinson and Company
6.17 BGI Genomics Co. Ltd
6.18 Bioarray Genetics
6.19 Biocartis
6.20 Biocept, Inc.
6.21 Biodesix Inc.
6.22 BioFluidica
6.23 bioMérieux Diagnostics
6.24 Bioneer Corporation
6.25 Bio-Rad Laboratories, Inc
6.26 Bio-Techne
6.27 Bioview
6.28 Bolidics
6.29 Boreal Genomics
6.30 Caris Molecular Diagnostics
6.31 CellMax Life
6.32 Cepheid (now Danaher)
6.33 Chronix Biomedical
6.34 Circulogene
6.35 Clinical Genomics
6.36 Cynvenio
6.37 Cytolumina Technologies Corp.
6.38 CytoTrack
6.39 Datar Cancer Genetics Limited
6.40 Diagenode Diagnostics
6.41 Diagnologix LLC
6.42 Enzo Life Sciences, Inc.
6.43 Epic Sciences
6.44 Epigenomics AG.
6.45 Eurofins Scientific
6.46 Exosome Diagnostics
6.47 Exosome Sciences
6.48 Fluidigm Corp
6.49 Fluxion Biosciences
6.50 Foundation Medicine
6.51 Freenome
6.52 GeneFirst Ltd.
6.53 Genetron Health (Beijing) Co., Ltd.
6.54 Genomic Health
6.55 GILUPI Nanomedizin
6.56 Grail, Inc.
6.57 Guardant Health
6.58 HansaBiomed
6.59 HeiScreen
6.60 Helomics
6.61 Horizon Discovery
6.62 iCellate
6.63 Illumina
6.64 Incell Dx
6.65 Inivata
6.66 Integrated Diagnostics
6.67 Janssen Diagnostics
6.68 MDNA Life SCIENCES, Inc.
6.69 MDx Health
6.70 Menarini Silicon Biosystems
6.71 Millipore Sigma
6.72 Miltenyi Biotec
6.73 miR Scientific
6.74 Molecular MD
6.75 Myriad Genetics/Myriad RBM
6.76 NantHealth, Inc.
6.77 Natera
6.78 NeoGenomics
6.79 New Oncology
6.80 Novogene Bioinformatics Technology Co., Ltd.
6.81 Oncocyte
6.82 OncoDNA
6.83 Oxford Nanopore Technologies
6.84 Perkin Elmer
6.85 Personal Genome Diagnostics
6.86 PrecisionMed
6.87 Promega
6.88 Qiagen Gmbh
6.89 Quidel
6.90 Rarecells SAS
6.91 RareCyte
6.92 Resolution Biosciences, Inc
6.93 Roche Molecular Diagnostics
6.94 Screencell
6.95 Siemens Healthineers
6.96 simfo GmbH
6.97 Singlera Genomics Inc.
6.98 SRI International
6.99 Sysmex Inostics
6.100 Tempus Labs, Inc.
6.101 Thermo Fisher Scientific Inc.
6.102 Thrive Earlier Detection
6.103 Trovagene
6.104 Volition


7 The Global Market for Liquid Biopsy Diagnostics
7.1 Global Market Overview by Country
7.1.1 Table - Global Market by Country
7.1.2 Chart - Global Market by Country
7.2 Global Market by Cancer - Overview
7.2.1 Table - Global Market by Cancer
7.2.2 Chart - Global Market by Cancer - Base/Final Year Comparison
7.2.3 Chart - Global Market by Cancer - Base Year
7.2.4 Chart - Global Market by Cancer - End Year
7.2.5 Chart - Global Market by Cancer - Share by Year
7.2.6 Chart - Global Market by Cancer - Segments Growth
7.3 Global Market by Usage - Overview
7.3.1 Table - Global Market by Usage
7.3.2 Chart - Global Market by Usage - Base/Final Year Comparison
7.3.3 Chart - Global Market by Usage - Base Year
7.3.4 Chart - Global Market by Usage - End Year
7.3.5 Chart - Global Market by Usage - Share by Year
7.3.6 Chart - Global Market by Usage - Segments Growth
7.4 Global Market by Place - Overview
7.4.1 Table - Global Market by Place
7.4.2 Chart - Global Market by Place - Base/Final Year Comparison
7.4.3 Chart - Global Market by Place - Base Year
7.4.4 Chart - Global Market by Place - End Year
7.4.5 Chart - Global Market by Place - Share by Year
7.4.6 Chart - Global Market by Place - Segments Growth
7.5 Global Market by Marker - Overview
7.5.1 Table - Global Market by Marker
7.5.2 Chart - Global Market by Marker - Base/Final Year Comparison
7.5.3 Chart - Global Market by Marker - Base Year
7.5.4 Chart - Global Market by Marker - End Year
7.5.5 Chart - Global Market by Marker - Share by Year
7.5.6 Chart - Global Market by Marker - Segments Growth
7.6 Global Market by Product - Overview
7.6.1 Table - Global Market by Product
7.6.2 Chart - Global Market by Product - Base/Final Year Comparison
7.6.3 Chart - Global Market by Product - Base Year
7.6.4 Chart - Global Market by Product - End Year
7.6.5 Chart - Global Market by Product - Share by Year
7.6.6 Chart - Global Market by Product - Segments Growth


8 Global Liquid Biopsy Diagnostic Markets - By Cancer
8.1 Breast
8.1.1 Table Breast - by Country
8.1.2 Table Breast - by Country, Price
8.1.3 Table Breast - by Country Volume
8.1.4 Chart - Breast Growth
8.2 Colorectal
8.2.1 Table Colorectal - by Country
8.2.2 Table Colorectal - by Country, Price
8.2.3 Table Colorectal - by Country, Volume
8.2.4 Chart - Colorectal Growth.
8.3 Cervical
8.3.1 Table Cervical - by Country
8.3.2 Table Cervical - by Country, Price
8.3.3 Table Cervical - by Country, Volume
8.3.4 Chart - Cervical Growth
8.4 Lung
8.4.1 Table Lung - by Country
8.4.2 Table Lung - by Country, Price
8.4.3 Table Lung - by Country, Volume
8.4.4 Chart - Lung Growth
8.5 Prostate
8.5.1 Table Prostate - by Country
8.5.2 Table Prostate - by Country, Price
8.5.3 Table Prostate - by Country, Volume
8.5.4 Chart - Prostate Growth
8.6 Other
8.6.1 Table Other - by Country
8.6.2 Table Other - by Country, Price
8.6.3 Table Other - by Country, Volume
8.6.4 Chart - Other Growth
9 Global Liquid Biopsy Diagnostic Markets - by Usage
9.1 Screening
9.1.1 Table Screening - by Country
9.2 Chart - Screening Growth
9.3 Diagnostic
9.3.1 Table Diagnostic - by Country
9.3.2 Chart - Diagnostic Growth.
9.4 Therapy
9.4.1 Table Therapy - by Country
9.4.2 Chart - Therapy Growth
9.5 Monitor
9.5.1 Table Monitor - by Country
9.5.2 Chart - Monitor Growth


10 Global Liquid Biopsy Diagnostic Markets - by Place
10.1 Hospital Lab
10.1.1 Table Hospital Lab - by Country
10.1.2 Chart - Hospital Lab Growth
10.2 Lab Service
10.2.1 Table Lab Service - by Country
10.2.2 Chart - Lab Service Growth
10.3 Lab Outpatient
10.3.1 Table Lab Outpatient - by Country
10.3.2 Chart - Lab Outpatient Growth
10.4 Other Lab
10.4.1 Table Other Lab - by Country
10.4.2 Chart - Other Lab Growth


11 Global Liquid Biopsy Diagnostic Markets - by Marker
11.1 Circulating Tumor Cell
11.1.1 Table Circulating Tumor Cell - by Country
11.1.2 Chart - Circulating Tumor Cell Growth
11.2 Cell Free DNA
11.2.1 Table Cell Free DNA - by Country.
11.2.2 Chart - Cell Free DNA Growth
11.3 Vesicle
11.3.1 Table Vesicle - by Country
11.3.2 Chart - Vesicle Growth
11.4 Other Marker
11.4.1 Table Other Marker - by Country
11.4.2 Chart - Other Marker Growth
12 Global Liquid Biopsy Diagnostic Markets - by Product
12.1 Kits
12.1.1 Table Kits - by Country
12.1.2 Chart - Kits Growth
12.2 Instruments
12.2.1 Table Instruments - by Country
12.2.2 Chart - Instruments Growth
12.3 Service
12.3.1 Table Service - by Country
12.3.2 Chart - Service Growth


13 Appendices
13.1 United States Medicare System: 2021 Clinical Laboratory Fees Schedule


Table of Tables
Table 1  Market Players by Type
Table 2 Biopsy Sites
Table 3 Advantages of Liquid Biopsy in Screening Market
Table 4 Outlook - Phases of Liquid Biopsy Adoption by Year
Table 5 Five Factors Driving Growth
Table 6 Factors Limiting Growth
Table 7 Key Diagnostic Laboratory Technology Trends
Table 8 Next Generation Sequencing Technologies – Speed and Cost
Table 9 - Global Market by Region
Table 10 Global Market by Cancer
Table 11 Global Market by Usage
Table 12 Global Market by Place
Table 13 Global Market by Marker
Table 14 Global Market by Product
Table 15 Breast by Country
Table 16 Breast by Country Price
Table 17 Breast by Country Volume
Table 18  Colorectal by Country
Table 19 Colorectal by Country Price
Table 20 Colorectal by Country Volume
Table 21 Cervical by Country
Table 22 Cervical by Country Price
Table 23 Cervical by Country Volume
Table 24 Lung by Country
Table 25 Lung by Country Price
Table 26 Lung by Country Volume
Table 27 Prostate by Country
Table 28 Prostate by Country Price
Table 29 Prostate by Country Volume
Table 30 Other by Country
Table 31 Other by Country Price
Table 32 Other by Country Volume
Table 33  Screening by Country
Table 34 Diagnostic by Country
Table 35  Therapy by Country
Table 36  Monitor by Country
Table 37  Hospital Lab by Country
Table 38 Lab Service by Country
Table 39  Lab Outpatient by Country
Table 40  Other Lab by Country
Table 41  Circulating Tumor Cell by Country
Table 42 Cell Free DNA by Country
Table 43  Vesicle by Country
Table 44  Other Marker by Country
Table 45  Kits by Country
Table 46 Instruments by Country
Table 47  Service by Country
Table 48 2021 Clinical Lab Fee Schedule


Table of Figures
Figure 1 Global Healthcare Spending
Figure 2 The Lab Test Pie
Figure 3 Comparison of Liquid Biopsy Classes
Figure 4 Characteristics of Different Vesicle Types
Figure 5 Percentage of World Population Over 65
Figure 6  Global Market Regional Share Chart
Figure 7 Global Market by Cancer - Base vs. Final
Figure 8 Global Market by Cancer Base Year
Figure 9 Global Market by Cancer End Year
Figure 10 Cancer Share by Year
Figure 11 Cancer Segments Growth
Figure 12 Global Market by Usage - Base vs. Final
Figure 13 Global Market by Usage Base Year
Figure 14 Global Market by Usage End Year
Figure 15 Usage Share by Year
Figure 16 Usage Segments Growth
Figure 17 Global Market by Place - Base vs. Final
Figure 18 Global Market by Place Base Year
Figure 19 Global Market by Place End Year
Figure 20 Place Share by Year
Figure 21 Place Segments Growth
Figure 22 Global Market by Marker - Base vs. Final
Figure 23 Global Market by Marker Base Year
Figure 24 Global Market by Marker End Year
Figure 25 Marker Share by Year
Figure 26 Marker Segments Growth
Figure 27 Global Market by Product - Base vs. Final
Figure 28 Global Market by Product Base Year
Figure 29 Global Market by Product End Year
Figure 30 Product Share by Year
Figure 31 Product Segments Growth
Figure 32 Breast Growth
Figure 33 Colorectal Diagnostics Growth
Figure 34 Cervical Growth
Figure 35 Lung Growth
Figure 36 Prostate Growth
Figure 37 Other Growth
Figure 38 Screening Growth
Figure 39 Diagnostic Growth
Figure 40 Therapy Growth
Figure 41 Monitor Growth
Figure 42 Hospital Lab Growth
Figure 43 Lab Service Growth
Figure 44 Lab Outpatient Growth
Figure 45 Other Lab Growth
Figure 46 Circulating Tumor Cell Growth
Figure 47 Cell Free DNA Growth
Figure 48 Vesicle Growth
Figure 49 Other Marker Growth
Figure 50 Kits Growth
Figure 51 Instruments Growth
Figure 52 Service Growth